A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT06978699 | Recruiting Phase 2

• 1 other identifier: XH-S003-II-101
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

This is a multicenter, randomized, single-blind Phase II trial to evaluate the efficacy and safety of XH-S003 capsules in PNH patients. About 24 PNH patients will be enrolled and randomized to three dose levels and take XH-S003 capsules orally

Conditions

PNH - Paroxysmal Nocturnal Hemoglobinuria

Keywords

Paroxysmal Nocturnal Hemoglobinuria

Outcome Measures

Primary Outcomes (1)

• Changes of hemoglobin compared with baseline

  Changes of hemoglobin compared with baseline

  8 weeks

Secondary Outcomes (5)

• Proportion of subjects with an increase in Hb ≥20g/L compared with baseline (without RBC transfusion);

  8 weeks

• Changes in Indirect Bilirubin compared to baseline;

  8 weeks

• Changes in reticulocyte counts compared to baseline;

  8 weeks

• Proportion of subjects without RBC transfusion

  8 weeks

• Changes in LDH compared with baseline

  8 weeks

Study Arms (3)

Dose 1

EXPERIMENTAL

Once daily

Drug: XH-S003 Capsule

Dose 2

EXPERIMENTAL

Once daily

Drug: XH-S003 Capsule

Dose 3

EXPERIMENTAL

Once daily

Drug: XH-S003 Capsule

Interventions

XH-S003 Capsule DRUG

25mg \& 100mg

Dose 1; Dose 2; Dose 3

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Biological sex of eligible participants.
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female with aged ≥18 years old;
• Weight ≥40 kg and BMI≥18 kg/m2 ;
• Diagnosed with PNH: with red blood cell or granulocyte clone levels \>10% detected by flow cytopy within 6 months prior to screening or during screening;
• Patients who have not previously received any complement inhibitor therayp;
• LDH \> 1.5×ULN detected two times during the screening period (interval of 2 to 8 weeks);
• Hb meets one of the following conditions: (1) Hb \<100 g/L at the first screening visit, and subjects receive RBC transfusion because of PNH-related anemia during the screening period; (2) The average Hb of two tests during the screening period \<100 g/L (interval of 2\~8 weeks);
• Vaccination against Neisseria meningitidis and Streptococcus pneumoniae before the first administration. If the subject has not been vaccinated previously or requires booster vaccination (according to local vaccination policies), vaccination must be administered at least 2 weeks before the first administration. If the first administration must begin less than 2 weeks after vaccination, preventive antibiotic treatment must begin at least 2 weeks after vaccination;

You may not qualify if:

• Subjects with laboratory evidence of bone marrow failure during the screening period (reticulocyte count \<100×109/L, platelet count \<30×109/L, or neutrophil count \<0.5×109/L);
• Subjects receiving other therapies prior to screening who have not achieved the following treatment durations:
• Erythropoietin or immunosuppressants for at least 8 weeks; • Systemic corticosteroids for at least 4 weeks; • Iron supplements, vitamin B12, or folic acid for at least 4 weeks; • Anticoagulants: Vitamin K antagonists for at least 4 weeks with stable international normalized ratio (INR) (as determined by the investigator), low molecular weight heparin for at least 4 weeks; • Hypoxic-inducing factor prolyl hydroxylase inhibitors (HIF-PHI) for at least 8 weeks; • Androgens for at least 4 weeks;
• A history of bone marrow/hematopoietic stem cell or solid organ transplantation;
• Alanine aminotransferase (ALT), γ-glutamyl transpeptidase (GGT), or alkaline phosphatase (ALP) \>3×ULN at screening; - Positive HIV antibody, active syphilis infection, positive HBsAg, active HCV infection, or active tuberculosis infection at screening;
• Known or suspected immunodeficiency diseases or hereditary complement deficiency at screening;
• A history of Neisseria meningitidis infection;
• Subjects with chronic active or recurrent infections within 1 year prior to screening;
• Subjects with systemic active bacterial, viral (including COVID-19), or fungal infections within 2 weeks prior to the first administration; subjects with body temperature \>38°C within 7 days prior to the first administration;

Sponsors & Collaborators

• S-INFINITY Pharmaceuticals Co., Ltd: lead

Study Sites (1)

TianJin Medical University General Hospital

Tianjin, China

RECRUITING

MeSH Terms

Conditions

Hemoglobinuria, Paroxysmal

Condition Hierarchy (Ancestors)

Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Myelodysplastic Syndromes; Bone Marrow Diseases

Central Study Contacts

Rong Fu

CONTACT

+86-13920350233; furong8369@tmu.edu.cn

Hui Liu

CONTACT

+86-13821113189; liuhui8003@qq.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 8, 2025
• First Posted: May 18, 2025
• Study Start: April 30, 2025
• Primary Completion: August 30, 2025
• Study Completion (Estimated): October 30, 2026
• Last Updated: May 18, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)